Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.85 USD

88.85
926,404

-0.15 (-0.17%)

Updated Oct 28, 2024 12:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

by Zacks Equity Research

Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data

by Zacks Equity Research

It has been a busy week for the biotech sector with pipeline and regulatory updates from quite a few players.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $64.36 in the latest trading session, marking a +0.83% move from the prior day.

Sanghamitra Saha headshot

Wining & Losing ETF Areas on Coronavirus Outbreak

by Sanghamitra Saha

Coronavirus outbreak puts these ETF areas in winning and losing positions.

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

by Zacks Equity Research

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

by Zacks Equity Research

Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

by Sweta Killa

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $63.43, marking a +1.28% move from the previous day.

GILD or EXEL: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GILD vs. EXEL: Which Stock Is the Better Value Option?

Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

by Zacks Equity Research

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

Nektar's Pain Drug Gets Adverse Advisory Committee Decision

by Zacks Equity Research

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $64.31, moving -1.11% from the previous trading session.

The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Accenture, Adobe Systems, Gilead Sciences and Honda Motor

Sheraz Mian headshot

Stock Research Reports for Chevron, Accenture, Adobe & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Accenture (ACN) and Adobe Systems (ADBE).

Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

by Zacks Equity Research

Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

Agenus Initiates Phase I Study on Oncology Candidate AGEN1223

by Zacks Equity Research

Agenus (AGEN) initiates phase I study on AGEN1223, a novel bi-specific antibody designed to deplete regulatory T cells in the tumor micro environment.

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $65.12, marking a -0.81% move from the previous day.

Novo Nordisk's Shares Up in a Year on Pipeline Progress

by Zacks Equity Research

Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.

GILD vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GILD vs. TECH: Which Stock Is the Better Value Option?

Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down

by Zacks Equity Research

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

    Gilead (GILD) Partners With Eisai for RA Candidate in Japan

    by Zacks Equity Research

    Gilead Sciences (GILD) collaborates with Eisai for the distribution and co-promotion of its rheumatoid arthritis candidate, filgotinib. The companies will jointly commercialize the drug, if approved.

    Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    Gilead Sciences (GILD) closed the most recent trading day at $66.72, moving -0.04% from the previous trading session.

    GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA

    by Zacks Equity Research

    GlaxoSmithKline's (GSK) ViiV Healthcare receives a CRL from the FDA for its application seeking approval of its investigational long-acting injectable therapy, which is a combination of cabotegravir and J&J's Edurant.